4/A: Robert Duggan Increases Stake in Pulse Biosciences

Director and 10% owner Robert W. Duggan acquired 660,233 shares of Pulse Biosciences common stock through an at-the-market offering.

Summary

• Reporting person Robert W. Duggan purchased 660,233 shares of Pulse Biosciences (PLSE) common stock.
• The transaction occurred on May 11, 2026, at a price of $19.69 per share.
• The acquisition was executed via the company's at-the-market (ATM) equity offering program.
• Following this transaction, the reporting person's direct beneficial ownership increased to 48,370,047 shares.
• The filing serves as an amendment to correct a minor reporting omission of 700 shares.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal, as significant insider buying typically indicates that management believes the current market valuation does not fully reflect the company's future potential.

Positives

• Significant insider confidence demonstrated by the purchase of over 660,000 shares.
• The purchase price of $19.69 reflects active participation in the company's capital raising efforts.
• The reporting person maintains a substantial long-term equity position in the issuer.

Negatives

• The filing indicates an initial reporting error regarding 700 shares, necessitating this amendment.

Risks

• Reliance on at-the-market equity offerings can lead to shareholder dilution.
• Concentrated ownership by a single director/shareholder may influence corporate governance outcomes.

Future Outlook

The company continues to utilize its at-the-market equity offering program as a mechanism for capital raising as established in the February 2026 agreement.

Management Comments

• The shares were purchased during an open trading window under the Company's Insider Trading Policy.

Industry Context

StockSavvy.ai notes that insider buying of this magnitude in a biotech firm often signals strong management conviction in the company's clinical pipeline or commercialization strategy, contrasting with broader market trends where insiders may be selling to lock in gains.

Comparison to Industry Standards

• The use of ATM programs is a standard capital-raising tool for mid-cap biotechnology companies to fund R&D without the volatility of a traditional underwritten offering.
• The level of insider ownership by Robert Duggan is significantly higher than the industry average for comparable medical device and biotech firms.

Related Party Transactions

• The reporting person holds shares through affiliated entities Genius 24C Inc. and Blazon Corporation.

Stakeholder Impact

• Shareholders may view the insider purchase as a vote of confidence.
• The ongoing ATM program may result in continued dilution of existing equity.

Next Steps

• Continued monitoring of the ATM program utilization.
• Future SEC filings regarding changes in beneficial ownership.

Key Dates

Recommendation

While insider buying is a bullish indicator, the reliance on ATM offerings suggests potential future dilution, warranting a hold position until further clinical or commercial milestones are achieved.

Keywords

Pulse Biosciences, PLSE, Insider Trading, Robert Duggan, Equity Offering, SEC Form 4